Allergan Plc (AGN)

[DewDiligence]

AGN 1Q18 items…

PR:
http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNjk5NDV8Q2hpbGRJRD02OTI4MTE=

CC slides:
http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNjk5NDV8Q2hpbGRJRD02OTI4MjE=

[MinnieM]

Update http://www.scotusblog.com/2018/04/opinion-analysis-justices-rebuff-constitutional-attack-on-administrative-re-examination-of-patents/

[DewDiligence]

RVNC Investor Day PR and slide set:

#msg-140163667
https://t.co/375njX9EXq

[MinnieM]

$AGN - Mohawk Tribe wins stay from Federal Circuit in sovereign immunity fight
http://www.ipwatchdog.com/2018/03/28/mohawk-tribe-wins-stay-federal-circuit-sovereign-immunity-fight/id=95371/

[MinnieM]

$AGN Update on their move to protect patent from IPR process by giving it to St Regis Mohawk Tribe. The PTAB decided to deny the motion to terminate the proceedings.
https://www.patentprogress.org/wp-content/uploads/2018/02/PTAB-Denial-Of-Sovereign-Immunity-In-Allergan-IPRs.pdf

Allergan and the St. Regis Mohawk Tribe are fighting it.
https://www.jdsupra.com/legalnews/st-regis-mohawk-tribe-and-allergan-file-74636/

[DewDiligence]

RVNC, MYL collaborate on Botox biosimilar:

#msg-138919637
#msg-138921300

[DewDiligence]

AGN 4Q17 items…

PR:
http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNjcxNzR8Q2hpbGRJRD02ODc3Mjk=

CC slides:
http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNjcxNzR8Q2hpbGRJRD02ODc3MzA=

[T695]

Thanks for the heads up

[DewDiligence]

There's a lot of discussion of AGN (especially Botox) on #board-1418.

[T695]

This stock has been moving nicely, I’m surprised there’s no one here

[DewDiligence]

1/12/18 Morningstar rpt on AGN (quite comprehensive):

http://news.morningstar.com/articlenet/article.aspx?id=843274

[DewDiligence]

AGN webcast at JPM—>1/8/18, 6pm ET.

[T695]

Maybe the reversal starts today

[T695]

Why is this board not connected to the ticker??

[DewDiligence]

Transcript of AGN’s 3Q17 CC:

https://finance.yahoo.com/news/edited-transcript-agn-earnings-conference-220554384.html

See #msg-135879183 for portion of CC relevant to Botox competition from RVNC.

[193638]

anyone looking to buy today?

[DewDiligence]

3Q17 worldwide Botox sales=$775M: #msg-135855769.

[DewDiligence]

AGN 3Q17 CC slides:

http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNjM5NjJ8Q2hpbGRJRD02ODMxNTk=

[MinnieM]

$AGN - Allergan Was Correct To Fight The Legal Theft Of Property
https://seekingalpha.com/article/4115423-allergan-correct-fight-legal-theft-property

[DewDiligence]

Adverse ruling on Restasis patent in US District Court:

https://finance.yahoo.com/news/u-district-court-eastern-district-174500864.html

Allergan plc…today acknowledged that the U.S. District Court for the Eastern District of Texas has issued an adverse trial decision finding that the four asserted patents covering RESTASIS (Cyclosporine Ophthalmic Emulsion) 0.05% are invalid. The Company will appeal the Court's ruling.

…The patents include United States Patent Nos. 8,629,111; 8,648,048; 8,685,930 and 9,248,191. These patents, along with United States Patent Nos. 8,633,162 and 8,642,556, are listed in the Orange Book for RESTASIS and expire on August 27, 2024.

Unless overturned on appeal, the Districtt Court’s ruling blows up AGN’s patent settlement with PFE (#msg-135360904).

[DewDiligence]

AGN, PFE settle Restasis-patent litigation: #msg-135360904.

[DewDiligence]

AGN authorizes $2B buyback and increased dividend: #msg-134875241.

[DewDiligence]

AGN reports mixed phase-2b NASH data:

https://finance.yahoo.com/news/data-centaur-phase-2b-clinical-120000624.html

In the patients who remained on treatment for two years, there was no significant difference between CVC and placebo in the composite endpoint – reduction in fibrosis by at least one stage with no worsening of NASH. However, in patients with higher baseline fibrosis scores, patients who received CVC had better outcomes during the two year treatment period.

CVC is the drug AGN obtained in the controversial buyout of Tobira (#msg-125266132).

[Inoviorulez]

https://seekingalpha.com/article/4107923-amgen-allergan-avastin-biosimilar-approval-part-2

[DewDiligence]

AGN’s novel ploy to protect Restasis exclusivity: #msg-134477923.

[DewDiligence]

AGN 2Q17 CC slides:

http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNTg4ODV8Q2hpbGRJRD02NzcwNjg=

[DewDiligence]

2Q17 Botox sales by category: #msg-133533732.

[DewDiligence]

ODAC endorsed AMGN/AGN’s Avastin FoB by unanimous vote:

https://www.medpagetoday.com/hematologyoncology/chemotherapy/66608

[DewDiligence]

AGN 1Q17 items…

PR:
http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNTMzMDR8Q2hpbGRJRD02NzAzMjY=

CC slides:
http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNTMzMDR8Q2hpbGRJRD02NzAzMjU=

[hiwatt1959]

Does AGN have a way around the new patent by Rprx for SPRM drugs treating uterine fibroids? AGN did use an "off drug interval" on Venus 2 P3. Note they mention Esmya (Ulipristal Acetate) in PR.
Repros Announces the Issuance of New U.S. Patent Relating to Treatment Using Off Drug Intervals For Certain Uterine Conditions
THE WOODLANDS, Texas, April 17, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced the issuance of a new patent, U.S. Patent number 9,616,074 (the ‘074 patent), that bolsters the Company's intellectual property relating to Proellex® (telapristone acetate). The ‘074 patent, which expires in 2027, relates to the use of Selective Progesterone Receptor Modulators (SPRM), in particular Telapristone Acetate (Proellex®) or Ulipristal Acetate, with an Off Drug Interval (ODI) for the treatment of estrogen-dependent hyperproliferative uterine conditions, such as uterine fibroids and endometriosis. Under the terms of the patent, ODI is defined as daily administration of the SPRM for a period of time, followed by an ODI sufficient for the patient to menstruate and then by another period of administration of the SPRM.

[DewDiligence]

NVS, AGN collaborate on phase-2b for NASH combo: #msg-130568056.

[DewDiligence]

AGN moves Botox to phase-3 in depression despite tepid phase-2 data and lack of dose response:

#msg-130222123
#msg-130222168

[DewDiligence]

Why Kybella has disappointed: #msg-129497650.

[DewDiligence]

AGN, EDIT ink drug-discovery collaboration for eye diseases: #msg-129491806.

[DewDiligence]

FDA approves Noctiva for frequent nighttime urination: #msg-129243463.

[DewDiligence]

4Q16 Botox sales: $729M, +14% YoY: #msg-128533148.

[DewDiligence]

AGN 4Q16 items…

PR:
http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNDYzNjh8Q2hpbGRJRD02NTk2NTQ=

CC slides:
http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNDYzNjh8Q2hpbGRJRD02NTk2NTM=

[semi_infinite]

Option pricing suggest a move of ~$10 or around 4% in either direction.

[ValueInvestor15]

Allergan $AGN valuation models shows 14% upside b4 earnings Wednesday...

Fair Value Analysis

[ValueInvestor15]

5 Manufacturing Stocks with 25% Upside Potential: AGN

Full Analysis

[DewDiligence]

AGN acquires (private) LifeCell for $2.9B cash: #msg-127307118.

[north40000]

Further discussion of Dry Eye Syndrome[DES]:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127432/pdf/opth-10-2337.pdf


Eicosapentaenoic acid (EPA), docosahexaenoic acid
(DHA), and alpha linolenic acid (ALA) are the three omega-3
fatty acids that cannot be synthesized in the body and
have to be supplemented in diet. EPA and DHA modulate
prostaglandin metabolism toward anti-inflammatory
prostaglandin synthesis due to competitive inhibition of
the arachidonic acid pathway.48 Omega-3 supplementation
demonstrates an anti-inflammatory effect, inhibiting creation
of omega-6 prostaglandin precursors, preventing apoptosis
of the secretory epithelial cells in the lacrimal gland, and
clearing meibomitis, which allows for a healthier lipid layer
to protect the tear film and cornea.49
Therapeutic responses from topical anti-inflammatory
agents do not result in significant clinical improvement in
more than half the patients treated.35,50 This is evidenced by
moderate, or complete, regression of symptoms in only 43%,
or 57%, respectively, of dry eye patients with delayed clearance
following treatment with loteprednol.51 Similarly, treatment
with topical cyclosporine 0.1% for 6 months showed
only moderate response to treatment in 39% of symptomatic
dry eye patients.50....{more]

[north40000]

IMO, both AGN and MYL will have difficulty competing against Amarin's Vascepa for Dry Eye syndrome[DES]. The DES I once had for several years[making the wear of contact lenses difficult and uncomfortable] was wiped out by Vascepa within a week of my initiation of therapy employing FDA-approved Vascepa, off-label, for unrelated conditions in April 2013:

https://dl.dropboxusercontent.com/u/57678878/EPA%20Compilation%20Rev2.5.pdf
Note item 9, page 33

http://www.fdalawblog.net/Amarin%20%2800193135%29.pdf
http://tinyurl.com/zyduacf
http://tinyurl.com/j6gjg4b

Vascepa is a comparatively low cost therapy. Dosage is 4 capsules/day, each capsule containing 1 g of 96% icosapent ethyl, an omega-3 fatty acid ester.

[DewDiligence]

MYL obtains IPRs on several Restatis patents:

http://finance.yahoo.com/news/allergan-comments-ptab-decision-regarding-203900309.html

Restasis is AGN’s second-largest drug (after Botox).

[Tradescott818]

Wow what a beating
Picked up 200 shares will add more after the bottom of 186 is confirmed

[DewDiligence]

AGN 3Q16 CC slides:

http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyMzk4ODN8Q2hpbGRJRD02NTEyMDM=

[DewDiligence]

AGN announces $10B buyback authorization—and first-ever dividend (starting in 2017):

#msg-126248044

[DewDiligence]

AGN reports 3Q16 results—Botox leads the way:

#msg-126247569

[DewDiligence]

AGN licenses AZN’s MEDI2070—an IL-23 inhibitor: #msg-125539596.

[DewDiligence]

AGN CC slides:

http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyMzcyNzJ8Q2hpbGRJRD02NDYwMjk=